Analyst Price Targets — NAGE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 5, 2026 11:49 am | — | Roth Capital | $10.00 | $3.47 | TheFly | Niagen Bioscience price target lowered to $10 from $12 at Roth Capital |
| May 11, 2026 10:03 am | — | H.C. Wainwright | $11.00 | $4.17 | TheFly | Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright |
| May 5, 2026 10:48 am | — | Canaccord Genuity | $10.00 | $4.93 | TheFly | Niagen Bioscience price target lowered to $10 from $13 at Canaccord |
| November 5, 2025 2:21 pm | — | Canaccord Genuity | $14.00 | $7.03 | TheFly | Niagen Bioscience price target lowered to $14 from $16 at Canaccord |
Latest News for NAGE
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or…
Niagen Bioscience, Inc. (NASDAQ: NAGE - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary driver of NAD+ decline in aging…
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BioPharma--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company's small molecule…
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's Well Summit, taking place from September 28 to 30, 2026, in New York. Mr.…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NAGE.
U.S. House Trading
No House trades found for NAGE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.